EVELIQURE BIOTECHNOLOGIES GMBH - TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.

On Dec 31, 2025, Department of Health and Human Services obligated $11,480,629.99 to EVELIQURE BIOTECHNOLOGIES GMBH for to advance the development of the shigetec vaccine through cgmp manufacturing and release of additional cgmp lots for use in a series of phase 2 clinical trials.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 4 offers received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Mar 31, 2027 — approximately 10 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.